Start of construction work on a new filling finishing facility in Morocco

Global Contract Development and Manufacturing Organization ( CDMO ) Recipharm, in charge of shaping the new entity SENSYO Pharmatech, attended a ceremony to recognize the launch of the construction works of its new filling finishing plant in Morocco. The ceremony was presided over by His Majesty the King of Morocco, Mohammed VI, in the province of Benslimane, and marks the beginning of a new era of vaccine Morocco’s independence.

This is a major investment in the site by the Moroccan government, a consortium of the country’s leading banks and Recipharm over the next five years to establish both Recipharm’s capacity and capability to manufacture vaccines and biotherapeutic products in the Kingdom. This investment is a new step towards effective management of the pandemic and will help ensure the Kingdom’s self-sufficiency in vaccines and the supply of the entire African continent.

The facility, called SENSYO Pharmatech, is part of Her Majesty’s vision to position Morocco as a key hub biotechnology hub capable of meeting the short and long-term health needs of African populations by integrating pharmaceutical research, clinical development, manufacturing and marketing of pharmaceutical products.

SENSYO Pharmatech aims to be the largest fill and finish platform in Africa. Initially, it will focus on the manufacture and syringe of vaccines and will include three industrial lines which should produce more than 100 million units in 2024. These lines will be dedicated to the production of vials and vaccines in syringes. It is built on a virgin site of 60 hectares and should be operational by 2023.

“We are proud to be involved as the CDMO of choice in this fantastic breakthrough for Morocco and Africa,” said Marc Funk, CEO of Recipharm. “The inauguration of a facility of this magnitude is an important milestone and reflects the depth of our shared commitment to meeting Morocco’s long-term healthcare needs.

“The past two years have shown the importance of a reliable vaccine supply, and we are honored to have been asked to use our expertise and experience in filler-finish manufacturing to produce vaccines and other products. biotherapeutics in Morocco. Together with all concerned, we will work to ensure that countries in Africa have better access to the health care they need.

Between 2022-2025, the objective is to transfer the aseptic filling and the manufacture of active substances of more than 20 vaccines and biotherapeutic products, including three Covid-19 vaccines to meet the needs of populations in Morocco and Africa.